Alphamab Oncology (HKG:9966) Full Year 2024 Results
Key Financial Results
- Revenue: CN¥640.1m (up 193% from FY 2023).
- Net income: CN¥166.3m (up from CN¥210.6m loss in FY 2023).
- Profit margin: 26% (up from net loss in FY 2023). The move to profitability was driven by higher revenue.
- EPS: CN¥0.17 (up from CN¥0.22 loss in FY 2023).
9966 Products In Clinical Trials
- Phase I: 4.
- Phase II: 14.
9966 Post-Clinical Trial Products
- Pre-registration: 1.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Alphamab Oncology Revenues and Earnings Beat Expectations
Revenue exceeded analyst estimates by 90%. Earnings per share (EPS) also surpassed analyst estimates.
Looking ahead, revenue is forecast to grow 32% p.a. on average during the next 3 years, compared to a 25% growth forecast for the Biotechs industry in Hong Kong.
Performance of the Hong Kong Biotechs industry.
The company's shares are up 14% from a week ago.
Risk Analysis
Be aware that Alphamab Oncology is showing 1 warning sign in our investment analysis that you should know about...
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.